Search for a command to run...
BACKGROUND: Assessment of the need for prevention of decreased bone mineral density in young individuals with Hodgkin lymphoma after pathogenetic therapy is relevant, as they face an increased risk of such long-term complications as frequent fractures. AIM: This study aimed to develop prognostic models for assessing the need for prevention of decreased bone mineral density in young patients with Hodgkin lymphoma after standard pathogenetic therapy. METHODS: This single-center cross-sectional study included 93 participants: 63 patients with an established diagnosis of Hodgkin lymphoma and 30 healthy volunteers aged 17–45 years. The study was conducted at the Department of Oncohematology, Chemotherapy, and Bone Marrow Transplantation of the Sverdlovsk Regional Clinical Hospital No. 1 (Yekaterinburg). Data were collected from 2018 to 2023. Each participant completed a questionnaire recommended by the Institute of Rheumatology to assess fracture risk factors. Dual-energy x-ray absorptiometry was performed in all patients to evaluate bone tissue status. The models were constructed using multivariate logistic regression. Model performance was assessed by the area under the ROC curve (AUC), as well as by accuracy, sensitivity, and specificity. RESULTS: Two models were developed to assess the risk of osteoporosis and the need for early initiation of preventive measures for decreased bone mineral density in patients with Hodgkin lymphoma. The first model, based on questionnaire results, had an AUC of 0.727, accuracy of 71.4%, sensitivity of 75%, and specificity of 66.7%. The second model, which included densitometric parameters, demonstrated higher performance: ROC-AUC of 0.95, accuracy of 88.6%, sensitivity of 95%, and specificity of 80%. CONCLUSION: Both models may be used as screening tools; however, the model based on densitometric parameters has higher diagnostic performance. The use of the model without densitometric data appears acceptable for preliminary identification of indications for preventive measures in patients with Hodgkin lymphoma.